Node-Positive Breast Cancer
In node-positive women where the risk of relapse and death is higher, more intensive cytotoxic chemotherapies have been studied. The use of anthracycline-based regimens has led to improved results vs CMF-type regimens in this group of women.
Direct comparisons of an anthracycline-based regimen with classical CMF have shown significant improvement almost exclusively in trials in which the schedule of the anthracycline-based regimen was similar and the regimens were of similar duration to classical CMF.[48,49]
Trials of high-dose chemotherapy with marrow or peripheral blood stem cell support have failed to show improvement of treatment outcome.[33,34,36] Initial enthusiasm for the introduction of taxanes, specifically paclitaxel added to AC in node-positive breast cancer, has waned with further follow-up and presentation of a second trial of similar design and size, suggesting that the addition of paclitaxel after 4 courses of AC may be effective only in patients with endocrine-nonresponsive.
7th International Conference
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.